BRAFV600E mutant cutaneous melanomas are dependent on MAPK signaling for cell-cycle progression and proliferation, and have high sensitivity to type I BRAF inhibitors and to MEK inhibitors [7-10]. This evidence concerns the gene MAP2K7 and cutaneous melanoma.